Context Therapeutics Q1 net loss widens on higher R&D costs

Context Therapeutics

06/05/2026 21:38

Overview

US biopharma developer's Q1 net loss widened yr/yr on higher R&D expenses

Company expects cash position to fund operations into mid-2027

FDA granted Fast Track designation to lead candidate for ovarian cancer

Outlook

Company expects Phase 1a interim data for CTIM-76 trial in June 2026

Phase 1a interim data for CT-95 trial expected in September 2026

Company expects cash and cash equivalents to fund operations into mid-2027

Result Drivers

HIGHER R&D EXPENSES - Increased spending on CTIM-76, CT-202, CT-95 programs and higher personnel-related costs drove up R&D expenses

HIGHER ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher salaries, share-based compensation, and professional fees

LOWER INTEREST INCOME - Other income declined due to lower interest income on cash and cash equivalents

Company press release: ID:nGNX5nTPQM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$8.70 mln
Q1 Basic EPS
-$0.09


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Context Therapeutics Inc is $5.50, about 125.4% above its May 5 closing price of $2.44

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)